1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Mepolizumab Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 100mg Pre‑filled Syringe
  • 1.3.3 100mg Lyophilized Powder for Injection
• 1.4 Market Analysis by Combination Therapy
  • 1.4.1 Overview: Global Mepolizumab Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
  • 1.4.2 Combination of Mepolizumab and Inhaled Corticosteroids
  • 1.4.3 Combination of Mepolizumab and LABA
• 1.5 Market Analysis by Route of Administratio
  • 1.5.1 Overview: Global Mepolizumab Consumption Value by Route of Administratio: 2021 Versus 2025 Versus 2032
  • 1.5.2 Subcutaneous Injection
  • 1.5.3 Subcutaneous Infusion
• 1.6 Market Analysis by Sales Channel
  • 1.6.1 Overview: Global Mepolizumab Consumption Value by Sales Channel: 2021 Versus 2025 Versus 2032
  • 1.6.2 Hospital
  • 1.6.3 Retail
  • 1.6.4 Online
• 1.7 Market Analysis by Application
  • 1.7.1 Overview: Global Mepolizumab Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.7.2 Severe Eosinophilic Asthma
  • 1.7.3 Chronic Rhinosinusitis With Nasal Polyps
  • 1.7.4 Eosinophilic Granulomatosis With Polyangiitis
  • 1.7.5 Others
• 1.8 Global Mepolizumab Market Size & Forecast
  • 1.8.1 Global Mepolizumab Consumption Value (2021 & 2025 & 2032)
  • 1.8.2 Global Mepolizumab Sales Quantity (2021-2032)
  • 1.8.3 Global Mepolizumab Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 GSK, GlaxoSmithKline
  • 2.1.1 GSK, GlaxoSmithKline Details
  • 2.1.2 GSK, GlaxoSmithKline Major Business
  • 2.1.3 GSK, GlaxoSmithKline Mepolizumab Product and Services
  • 2.1.4 GSK, GlaxoSmithKline Mepolizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 GSK, GlaxoSmithKline Recent Developments/Updates

3 Competitive Environment: Mepolizumab by Manufacturer

• 3.1 Global Mepolizumab Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Mepolizumab Revenue by Manufacturer (2021-2026)
• 3.3 Global Mepolizumab Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Mepolizumab by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Mepolizumab Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Mepolizumab Manufacturer Market Share in 2025
• 3.5 Mepolizumab Market: Overall Company Footprint Analysis
  • 3.5.1 Mepolizumab Market: Region Footprint
  • 3.5.2 Mepolizumab Market: Company Product Type Footprint
  • 3.5.3 Mepolizumab Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Mepolizumab Market Size by Region
  • 4.1.1 Global Mepolizumab Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Mepolizumab Consumption Value by Region (2021-2032)
  • 4.1.3 Global Mepolizumab Average Price by Region (2021-2032)
• 4.2 North America Mepolizumab Consumption Value (2021-2032)
• 4.3 Europe Mepolizumab Consumption Value (2021-2032)
• 4.4 Asia-Pacific Mepolizumab Consumption Value (2021-2032)
• 4.5 South America Mepolizumab Consumption Value (2021-2032)
• 4.6 Middle East & Africa Mepolizumab Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Mepolizumab Sales Quantity by Type (2021-2032)
• 5.2 Global Mepolizumab Consumption Value by Type (2021-2032)
• 5.3 Global Mepolizumab Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Mepolizumab Sales Quantity by Application (2021-2032)
• 6.2 Global Mepolizumab Consumption Value by Application (2021-2032)
• 6.3 Global Mepolizumab Average Price by Application (2021-2032)

7 North America

• 7.1 North America Mepolizumab Sales Quantity by Type (2021-2032)
• 7.2 North America Mepolizumab Sales Quantity by Application (2021-2032)
• 7.3 North America Mepolizumab Market Size by Country
  • 7.3.1 North America Mepolizumab Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Mepolizumab Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Mepolizumab Sales Quantity by Type (2021-2032)
• 8.2 Europe Mepolizumab Sales Quantity by Application (2021-2032)
• 8.3 Europe Mepolizumab Market Size by Country
  • 8.3.1 Europe Mepolizumab Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Mepolizumab Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Mepolizumab Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Mepolizumab Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Mepolizumab Market Size by Region
  • 9.3.1 Asia-Pacific Mepolizumab Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Mepolizumab Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Mepolizumab Sales Quantity by Type (2021-2032)
• 10.2 South America Mepolizumab Sales Quantity by Application (2021-2032)
• 10.3 South America Mepolizumab Market Size by Country
  • 10.3.1 South America Mepolizumab Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Mepolizumab Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Mepolizumab Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Mepolizumab Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Mepolizumab Market Size by Country
  • 11.3.1 Middle East & Africa Mepolizumab Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Mepolizumab Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Mepolizumab Market Drivers
• 12.2 Mepolizumab Market Restraints
• 12.3 Mepolizumab Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Mepolizumab and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Mepolizumab
• 13.3 Mepolizumab Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Mepolizumab Typical Distributors
• 14.3 Mepolizumab Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Mepolizumab market size was valued at US$ 2732 million in 2025 and is forecast to a readjusted size of US$ 7259 million by 2032 with a CAGR of 16.3% during review period.
Mepolizumab is a humanized anti‑interleukin‑5 (IL‑5) monoclonal antibody drug. It specifically targets and binds to the IL‑5 cytokine, blocks its combination with receptors on the surface of eosinophils, and inhibits the activation, proliferation and survival of eosinophils, thereby reducing eosinophilic inflammatory responses in the respiratory tract and the whole body. It is mainly applied in the treatment of inflammatory diseases such as eosinophilic asthma and chronic rhinosinusitis with nasal polyps. With stable clinical efficacy and favorable safety, it can effectively reduce the risk of severe exacerbations and provide a long‑acting targeted treatment option for eosinophil‑related respiratory diseases.In 2025, global Mepolizumab (Nucala) production reached approximately 1.71 million vials.
Mepolizumab, the world’s first approved anti‑IL‑5 monoclonal antibody, targets eosinophil‑related diseases mediated by interleukin‑5. It has built a diversified product portfolio centered on severe asthma, with gradually expanded indications including chronic rhinosinusitis with nasal polyps and eosinophilic granulomatosis with polyangiitis. Its market development is driven by the popularization of precision diagnosis and treatment as well as the general shift toward biological agents. Global regulatory authorities continue to expand its applicable populations and age ranges, meanwhile promoting its penetration from hospital settings to outpatient and home care scenarios. In terms of competition, GSK occupies a leading position, continuously optimizing its indication spectrum through clinical research and developing next‑generation long‑acting formulations to improve patient compliance and market competitiveness. Regional market growth benefits from improved medical infrastructure and rising awareness of rare and refractory inflammatory diseases, with emerging markets such as the Asia‑Pacific region showing great growth potential. Overall, key market drivers include improved diagnostic capabilities, greater accessibility of biological drugs, and optimized long‑term treatment costs. Major challenges involve difficulties in target patient screening, inconsistent reimbursement policies, and competition from similar therapeutic drugs. The overall industry development is characterized by indication expansion, regional market penetration and continuous product iteration.
This report is a detailed and comprehensive analysis for global Mepolizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Mepolizumab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Mepolizumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Mepolizumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Mepolizumab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Mepolizumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Mepolizumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, GlaxoSmithKline, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Mepolizumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
100mg Pre‑filled Syringe
100mg Lyophilized Powder for Injection
Market segment by Combination Therapy
Combination of Mepolizumab and Inhaled Corticosteroids
Combination of Mepolizumab and LABA
Market segment by Route of Administratio
Subcutaneous Injection
Subcutaneous Infusion
Market segment by Sales Channel
Hospital
Retail
Online
Market segment by Application
Severe Eosinophilic Asthma
Chronic Rhinosinusitis With Nasal Polyps
Eosinophilic Granulomatosis With Polyangiitis
Others
Major players covered
GSK, GlaxoSmithKline
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Mepolizumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Mepolizumab, with price, sales quantity, revenue, and global market share of Mepolizumab from 2021 to 2026.
Chapter 3, the Mepolizumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Mepolizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Mepolizumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Mepolizumab.
Chapter 14 and 15, to describe Mepolizumab sales channel, distributors, customers, research findings and conclusion.